ClinicalTrials.gg
Enrolling by invitationNCT06843811Updated Mar 31, 2026

Sirolimus for Leigh Syndrome

A Phase 2 interventional study of Sirolimus in Leigh Syndrome, sponsored by Matthew Demczko. Enrolling by invitation at 1 site in United States. Open to participants aged 6 Months to 55 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Matthew Demczko · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
6 Months to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.

Started
2025
the only one that year
Phase 2
5 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Matthew Demczko

Among the 14 studies in Leigh Disease with a site in United States, this one is the only one that started in 2025, is one of 5 in phase 2, and was the 14th registered.

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

Browse Leigh Disease studies →

Open to participants now

6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 6 Months to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leigh Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the drug Sirolimus in participants with Leigh syndrome.

Read the detailed description

This is a pilot phase 2 study with long-term extension to evaluate the safety and efficacy of enteral sirolimus in patients with genetically-confirmed Leigh syndrome.

Sirolimus will be given daily at a starting dose of 0.8 to 1.3 mg/m2 depending on subject age, weight, and BSA (body surface area). Dosage will be adjusted as needed based on sirolimus trough level to maintain patients within a range of 5 to10 ng/mL, a level lower than what is targeted in renal transplant recipients. Patients will be followed through this study for up to 24 weeks in the active phase. Participants who are eligible for the long-term extension may choose to stay on drug for up to 2 years thereafter

03

Conditions studied

  • Leigh Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Months to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Genetically-confirmed diagnosis of Leigh syndrome with neurodevelopmental manifestations, which include documented developmental delay, developmental regression, or abnormal neurologic exam findings including but not limited to hypotonia, hypertonia, dystonia, chorea, nystagmus, ataxia, dysmetria, tremor or muscle weakness.
  2. Age 6 months to 55 years at the time of enrollment.
  3. Weight ≥ 5 kg at the time of enrollment.
  4. Adequate liver function as evidenced by total \< 1.5x (ULN) and liver function tests, (ALT) and aspartate aminotransferase (AST), \< 3x ULN.
  5. Adequate renal function as evidenced by (GFR) > 60 mL/min/1.73m2 (cystatin C for pediatric population).
  6. Normal hematologic parameters as defined as:

    1. (ANC) ≥ 1.0 x 109/L
    2. count ≥ 100,000/mm3 (100 x 109/L)
    3. ≥ 9 g/dL
  7. Non-fasting serum triglycerides and cholesterol \< 300 mg/dL.
  8. Serum amylase and lipase \< 2x ULN.
  9. Adequate immunoglobulin levels as outlined below that, in the opinion of the investigator, will not place the patient at increased risk of infection.

    1. Immunoglobulin G (IgG) ≥ 200 mg/dL
    2. Immunoglobulin M (IgM) ≥ 30 mg/dL
    3. Immunoglobulin A (IgA) ≥ 10 mg/dL
  10. All sexually active participants must agree to use effective :

    1. Females of must agree to use effective contraception without interruption from 28 days prior to starting Product (IP) throughout 3 months after last dose of IP and have a negative urine pregnancy test result at screening and agree to ongoing pregnancy testing during the course of the study.
    2. Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after the last dose of investigational drug.
  11. The patient or parent(s)/legal guardian(s) is/are willing and able to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator.
  12. The patient or the patient's parent(s)/legal guardian(s) understand(s) and voluntarily sign(s) the documents(s) prior to any study-related assessments/procedures being conducted.

Exclusion criteria

Exclusion Criteria:

  1. Cardiac ≤ 50 %, shortening fraction ≤ 25% on cardiac echocardiogram within one year of screening and/or severe end-organ hypo-perfusion syndrome (secondary to cardiac failure) resulting in lactic acidosis.
  2. Patients with implanted cardiac assist/medical devices (including pacemakers), unless device was implanted prophylactically, and the patient is clinically asymptomatic.
  3. In the opinion of the investigator, and/or echocardiogram alterations at the time of screening.
  4. Myocardial infarction within 6 months prior to enrollment.
  5. Symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, or unstable coronary artery disease.
  6. Prior history of to sirolimus or other mTOR (Mechanistic Target of Rapamycin inhibitors).
  7. Prior history of angioedema requiring treatment or cessation of a presumed causative agent.
  8. Planned surgical procedure during the study period.
  9. Confirmed or highly suspected immunodeficiency disorder(s), including but not limited to, common variable immune deficiency (CVID), complement deficiency, etc.
  10. Clinically significant proteinuria that requires ongoing medical therapy.
  11. Any uncontrolled psychiatric or medical condition which, in the opinion of the investigator, would interfere with the patient's participation in the study.
  12. Patients who are breastfeeding or are pregnant.
  13. History of solid organ transplant (kidney, liver, heart, lung) or bone marrow transplant.
  14. Treatment with any drug (i.e., a drug for which there is no approved indication), including an investigational drug for mitochondrial disease within 1 month prior to receiving the first dose of study drug (or within 3 months for a trial with an investigational biologic).
  15. Patients with confirmed or suspected increased intracranial pressure, pseudotumor cerebri (PTC)/idiopathic intracranial hypertension, and or papilledema.
  16. Currently active (other than adequately treated non-melanoma skin cancers [i.e., squamous cell and/or basal cell carcinoma], carcinoma in situ of the cervix, or other adequately treated carcinoma in situ) and/or ongoing treatment for malignancy are ineligible. Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for ≥ 1 year.
  17. Recent infection requiring systemic anti-infective treatment that was completed ≤ 14 days prior to enrollment.
  18. Uncontrolled diabetes mellitus, as defined by > 8%, despite adequate therapy.
  19. History of interstitial lung disease and/or pneumonitis.
  20. Use of strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4 () and/or p-glycoprotein (p-GP) within the 14 days prior to receiving the first dose of study drug. Additionally, use of any known CYP3A4 substrates with a narrow therapeutic window (e.g., fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfenadine) within the 14 days prior to receiving the first dose of study drug.
  21. Use of medications with a high risk of angioedema
  22. Known (HIV), active or infection(s).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Phase 2A

    Participants will receive Sirolimus for at least 24 weeks at a starting dose of 0.8 to 1.3 mg/m2 two (2) times daily.

    Drug: Sirolimus

  • Experimental
    Long-Term Extension

    Eligible participants may continue Sirolimus treatment for up to two (2) years.

    Drug: Sirolimus

Interventions

  • Sirolimus will be given at a starting dose of 0.8 to 1.3 mg/m2 twice daily, depending on subject age and weight.

    Also known as: Rapamune, Rapamycin

06

What researchers measure

Primary outcomes

  1. Rate of Adverse Events

    Adverse events will be measured according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Incidence of AEs will be reported.

    Time frame: Up to 2.5 years

  2. Rate of Intercurrent Infection and Hospitalization

    Each infection and hospitalization will be reported.

    Time frame: Up to 2.5 years

  3. Incidence of abnormal safety lab values

    Count of clinically significant changes from baseline in safety labs

    Time frame: Up to 2.5 years

  4. Sirolimus Trough Level

    Measure of Sirolimus level in the blood. Sirolimus dosage will be adjusted as needed in order to maintain a sirolimus trough level within a range of 5 to 10 ng/mL. The number of out-of-range results will be reported.

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Change in MM-COAST Score

    Mitochondrial Myopathy-Composite Assessment Tool (MM-COAST) is a composite assessment tool used to measure the domains of muscle strength, muscle fatigue, balance, dexterity, and exercise intolerance. Scores are assigned for each domain assessment, based on z-score or % decrement for muscle fatigue, summed and averaged to achieve a domain score. The mean domain score is reported as the MM-COAST Composite Score.

    Time frame: Baseline up to end of study (up to 2.5 years)

  2. Change in GMFM (Gross Motor Function Measure) Score

    The GMFM is a clinical tool used assess changes in gross motor functions in 5 dimensions (1. lying and rolling, 2. sitting, 3. crawling and kneeling, 4. standing, and 5. walking, running, and jumping). Each task is scored as 0-does not initiate, 1-initiates, 2-partially completes, and 3-completed. Item scores are summed to calculate raw and percent scores for each of the five dimensions. Dimension percent scores are averaged to obtain an overall total score.

    Time frame: Baseline up to end of study (up to 2.5 years)

  3. Change in Movement Disorder-Childhood Rating Score (MDCRS)

    The MDCRS is a scale used to evaluate the impact of movement disorder on patient motor function and daily living activities. Severity of movement disorder in different regions of the body at rest, and during specific tasks, is ranked from 0 (no movement disorder) to 4 (severe movement disorder). Item scores are summed to calculate total score, with a higher total score indicating greater overall impact of movement disorder on daily functioning.

    Time frame: Baseline up to end of study (up to 2.5 years)

  4. CGI Scale

    The CGI (Clinical Global Impression Scale) is a 3-item clinician-rated scale used to assess severity of illness, global improvement, and therapeutic response. Degree of global improvement for participants receiving sirolimus will be assessed by the investigator and rated on a scale 7-point scale based on improvement from baseline from 1 (very much improved) to 7 (very much worse). A lower score indicates greater response to treatment.

    Time frame: Baseline up to end of study (up to 2.5 years)

  5. Change in Barry-Albright Dystonia Scale (BADS)

    The Barry-Albright Dystonia Scale is used to assess dystonia in 8 bodily regions: eyes, mouth, neck, trunk, and each upper and lower extremity. Each bodily region is scored based on a scale from 0 (absent) to 4 (severe symptoms). Total BADS score ranges from 0 (dystonia absent) to 32 (severe dystonia).

    Time frame: Baseline up to end of study (up to 2.5 years)

  6. Change in Scale for the Assessment and Rating of Ataxia (SARA)

    The SARA is an 8-item performance-based scale that assesses ataxia. Patients are evaluated based on their ability to perform a series of tasks with a cumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia).

    Time frame: Baseline up to end of study (up to 2.5 years)

  7. Newcastle Pediatric Mitochondrial Disease Scale (NPMDS)

    The NPMDS evaluates the progression of mitochondrial disease in pediatric patients in 4 domains: current function, system specific involvement, current clinical assessment and quality of life. Domain scores are summed for total score with higher scores indicating worse conditions.

    Time frame: Baseline up to end of study (up to 2.5 years)

  8. Newcastle Adult Mitochondrial Disease Scale (NMDAS)

    Evaluation of disease progression in adults. Each question in the NMDAS section I-III has a possible score from 0-5. The total score is calculated by summing the scores obtained for each question. The higher the score the more severe the disease.

    Time frame: Baseline up to end of study (up to 2.5 years)

  9. Change in PEDI-CAT Score

    Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) is a test that evaluates daily functional activities. A t-score of 50 represents the function of the general population (SD of 10). A t-score below 30 reflects poor performance compared to the general population. The range for the scores are 20-80.

    Time frame: Baseline up to end of study (up to 2.5 years)

  10. Patient Global Impression of Change (PGIC)

    Patients rate their impression of overall change from baseline on a 7-point scale from 0 (no change or condition is worse) to 7 (a great deal better). PGIC indicates a patient's belief of treatment efficacy

    Time frame: Baseline up to end of study (up to 2.5 years)

  11. Change in PedsQL

    Pediatric Quality of Life Inventory (PedsQL) is a 23-item questionnaire that evaluates health-related quality of life that is reported as 3 summary scores including Physical Health, Psychosocial Health and School/Work, as well as a total score (sum of summary scores). Total score ranges from 0-100 with a higher score indicating better quality of life.

    Time frame: Baseline up to end of study (up to 2.5 years)

  12. Change in Karnofsky-Lansky

    Karnofsky Lansky Scale: 0-100. 0-40: Unable to care for self, requires equivalent of institutional or hospital care; disease may be progressing rapidly. 50-70: Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed. 80-100: Able to carry on normal activity and to work; no special care needed.

    Time frame: Baseline up to end of study (up to 2.5 years)

  13. Change in MFIS

    The MFIS (Modified Fatigue Impact Scale) evaluates fatigue using a total MFIS score (0-84), where higher scores indicate greater impact of fatigue on an individual's activities and scores above 38 are considered to be indicative of fatigue. The MFIS is calculated from the sum of three subscales: the Physical Subscale (0-36), the Cognitive Subscale (0-40), and the Psychosocial Subscale (0-8), where higher scores indicate a greater impact of fatigue in each domain.

    Time frame: Baseline up to end of study (up to 2.5 years)

07

Study locations

1 site
08

References and documents

Publications

  • Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A, Uhde L, Hui J, Wall VZ, Gagnidze A, Oh K, Wasko BM, Ramos FJ, Palmiter RD, Rabinovitch PS, Morgan PG, Sedensky MM, Kaeberlein M. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013 Dec 20;342(6165):1524-8. doi: 10.1126/science.1244360. Epub 2013 Nov 14. PubMed 24231806 ↗
  • Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, Rabinovitch PS, Suh Y, Kaeberlein M. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015 Jul 22;6:247. doi: 10.3389/fgene.2015.00247. eCollection 2015. PubMed 26257774 ↗
  • Tinker RJ, Falk MJ, Goldstein A, George-Sankoh I, Xiao R, Adang L, Ganetzky R. Early developmental delay in Leigh syndrome spectrum disorders is associated with poor clinical prognosis. Mol Genet Metab. 2022 Apr;135(4):342-349. doi: 10.1016/j.ymgme.2022.02.006. Epub 2022 Feb 19. PubMed 35216885 ↗
  • Zheng X, Boyer L, Jin M, Kim Y, Fan W, Bardy C, Berggren T, Evans RM, Gage FH, Hunter T. Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. Elife. 2016 Mar 23;5:e13378. doi: 10.7554/eLife.13378. PubMed 27008180 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843811
Lead sponsor
Matthew Demczko
Responsible party
Matthew Demczko (Sponsor-Investigator, Children's Hospital of Philadelphia) — Sponsor-investigator
First posted
Feb 25, 2025
Start date
Feb 27, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Matthew Demczko, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion